Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 7.
doi: 10.1111/hae.70163. Online ahead of print.

Acquired Bleeding Disorders Associated With Immune Checkpoint Inhibitors: An Update

Marco Tuccori  1 , Daniele Focosi  2 , Elena Arzenton  1 , Fabio Scapini  1 , Ugo Moretti  1 , Massimo Franchini  3
Affiliations

Acquired Bleeding Disorders Associated With Immune Checkpoint Inhibitors: An Update

Marco Tuccori et al. Haemophilia. .
No abstract available

PubMed Disclaimer

References

    1. Q. Yin, L. Wu, L. Han, et al., “Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Review,” Frontiers in Immunology 14 (2023): 1167975.
    1. E. Raschi, A. Mazzarella, I. C. Antonazzo, et al., “Toxicities With Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System,” Targeted Oncology 14, no. 2 (2019): 205–221.
    1. N. Abdel‐Wahab, M. Shah, and M. E. Suarez‐Almazor, “Adverse Events Associated With Immune Checkpoint Blockade in Patients With Cancer: A Systematic Review of Case Reports,” PLoS ONE 11, no. 7 (2016): e0160221.
    1. J. Hou, R. Xie, Z. Zhang, Q. Liu, Q. Xiang, and Y. Cui, “Hematologic Side Effects of Immune Checkpoint Inhibitor With or Without Chemotherapy in Patients With Advanced and Metastatic Gastrointestinal Cancer: A Systematic Review and Network Meta‐Analysis of Phase 3 Trials,” Frontiers in Pharmacology 14 (2023): 1163971.
    1. D. C. Moore, J. B. Elmes, J. R. Arnall, S. A. Strassels, and J. N. Patel, “Immune Checkpoint Inhibitor‐Induced Acquired Haemophilia: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System,” Haemophilia 28, no. 5 (2022): e145–e148.

LinkOut - more resources